Megan Garlapow, PhD

Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC, where she brings extensive experience in medical communications across diverse therapeutic areas. Dr Garlapow earned her BA in biology from the University of Chicago and her PhD in genetics from North Carolina State University. With a strong background in biomedical science and genetics, Dr Garlapow has held key roles in medical education and clinical genetics and genomics, where she honed her skills in developing strategic proposals, securing funding, delivering high-quality educational content, and composing engaging medical journalism pieces.

All articles by Megan Garlapow, PhD

Trimetazidine did not provide cardiac support in wild-type ATTR-CM

Trimetazidine did not improve heart function or exercise capacity in patients with wild-type transthyretin cardiac amyloidosis.
FDA evaluates supplemental application for vutrisiran to treat patients with ATTR-CM

If approved, vutrisiran would become the first U.S. treatment to treat both polyneuropathy and cardiomyopathy linked to ATTR.
Tafamidis shows long-term benefits in slowing ATTR-CM progression

Nine years of treatment with tafamidis prevented hospitalizations for heart failure in two patients with ATTR-CM.
Tafamidis reduced amyloid in ATTR-CM but showed no symptom improvement

The study results suggested that tafamidis may stabilize ATTR-CM progression rather than reverse its effects.
Single dose of ATTR therapy nucresiran reduced TTR levels, company says

Nucresiran showed potential as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM), Alnylam Pharmaceuticals said.
FDA approves acoramidis to treat ATTR-CM

The FDA says the drug is designed to reduce death and hospitalizations related to transthyretin cardiac amyloidosis (ATTR-CM).
Research suggests arginine holds prophylactic potential for patients at risk for ATTR-CM

Arginine helped stabilize TTR tetramers and prevented amyloid formation, showing its potential as a safe way to stave off ATTR-CM.
Sodium-glucose cotransporter-2 inhibitors could be useful for people with ATTR-CM

SGLT2is appeared to be safe for patients with ATTR-CM and may result in fewer hospitalizations and improved kidney function.
Study finds variability in signs of heart failure in patients with ATTR-CM

The study results highlighted the need to broaden diagnostic criteria for transthyretin amyloid cardiomyopathy, or ATTR-CM.